MNK inhibition sensitizes KRAS-mutant colorectal cancer to mTORC1 inhibition by reducing eIF4E phosphorylation and c-MYC expression

KRAS-mutant colorectal cancers (CRC) are resistant to therapeutics, presenting a significant problem for ~40% of cases. Rapalogs, which inhibit mTORC1 and thus protein synthesis, are significantly less potent in KRAS-mutant CRC. Using Kras-mutant mouse models and mouse- and patient-derived organoids...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Discov
Autori principali: Knight, John R. P., Alexandrou, Constantinos, Skalka, George L., Vlahov, Nikola, Pennel, Kathryn, Officer, Leah, Teodosio, Ana, Kanellos, Georgios, Gay, David M., May-Wilson, Sebastian, Smith, Ewan M., Najumudeen, Arafath K., Gilroy, Kathryn, Ridgway, Rachel A., Flanagan, Dustin J., Smith, Rachael C. L., McDonald, Laura, MacKay, Craig, Cheasty, Anne, McArthur, Kerri, Stanway, Emma, Leach, Joshua D., Jackstadt, Rene, Waldron, Joseph A., Campbell, Andrew D., Vlachogiannis, Georgios, Valeri, Nicola, Haigis, Kevin M., Sonenberg, Nahum, Proud, Christopher G., Jones, Neil P., Swarbrick, Martin E., McKinnon, Heather J., Faller, William J., Le Quesne, John, Edwards, Joanne, Willis, Anne E., Bushell, Martin, Sansom, Owen J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7611341/
https://ncbi.nlm.nih.gov/pubmed/33328217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-20-0652
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi